Sleep Disorders

The professor of neurology at Emory University School of Medicine spoke on the potential for the new AASM hypersomnolence guideline to educate providers treating patients with sleep disorders.

Internet-based cognitive behavioral therapy for insomnia program engagement was low and did not elicit a change in medication use or health care visits.

A recent study found that saffron had similar efficacy at both 14-mg and 28-mg doses, increasing melatonin levels but not cortisol.

The associate professor of neurology at Emory University School of Medicine provided an overview of the new guideline, which addresses narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 27, 2021.

Coauthor and member of the American Academy of Sleep Medicine board of directors, Lynn Marie Trotti, MD, MSc, discussed key takeaways from the new guideline, which encompasses the first updates since 2007.

Here's what is coming soon to NeurologyLive.

The new guideline addresses recent FDA-approved prescription medications to treat narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome.

Neurology News Network for the week ending August 21, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 20, 2021.

Investigators found that phase advance was associated with late-stage PD, mostly due to active offset advance, amplitude reduction, and weakened robustness.

After the FDA approval for Jazz Pharmaceuticals' oxybates combination therapy, Robert Iannone, MD, MSCE, offered insight into the potential effects the drug may have on the clinical care of patients with idiopathic hypersomnia.

γ-Hydroxybutyrate, known as GHB or oxybate, is a physiological compound present in the human body as both a precursor and degradation product of GABA.

Investigators found SESI-HRMS measurements could be useful for breath analysis in conjunction with OSA screening questionnaires.

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.

After years of only off-label, wake-promoting therapies available for use, the FDA has approved the first treatment for idiopathic hypersomnia, JZP-258 (Xywav; Jazz).

Adverse reactions were consistent with the known side effect profile of sodium oxybate and were generally mild or moderate in new data from the REST-ON trial (NCT02720744).

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 6, 2021.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 30, 2021.

Patients with neurological sequelae from COVID-19 were significantly more likely to die before discharge (22.2%) compared with non-neuro-COVID patients (14.4%).